Increased risk for heart failure seen in breast cancer survivors given trastuzumab rather than chemo alone.
Real-world data indicate that lower risk of heart failure hospitalization and death associated with use of sodium-glucose cotransporter-2 inhibitors is consistent in patients with T2D with both reduced and preserved ejection fraction.
Genetically predicted endogenous testosterone may have role in thromboembolism, heart failure, MI.
For patients with HFrEF, treatment with sacubitril/valsartan may aid in reducing the requirement for loop diuretics compared with enalapril.
Investigators evaluated the characteristics of obstructive sleep apnea symptom subtypes and examined their relationship with prevalent and incident cardiovascular disease in the Sleep Heart Health Study.
Decreased cardiomyopathy risk seen for daunorubicin vs doxorubicin in survivors of childhood cancer.
Heart failure risk was significantly associated with countries which had greater income inequality.
Investigators assessed the frequency of missed diagnosis of new-onset systolic heart failure at first presentation in children with no known heart disease.
Investigators evaluated the value of the Barthel Index (BI) to predict 30-day mortality risk among patients with acute heart failure who go to the emergency department.
The MEESSI-AHF can accurately predict 30-day mortality in patients with acute heart failure.